Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Rheumatoid Arthritis
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial found that upadacitinib was more effective than placebo and adalimumab in adults with RA who had an inadequate response to MTX.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.